共查询到20条相似文献,搜索用时 140 毫秒
1.
1例43岁女性患者因肩周炎服用塞来昔布胶囊0.2g,2次/d,共服用2周。末次服药后2h上腹出现持续性钝痛,伴腹胀、恶心、呕吐。实验室检查示血清淀粉酶1822U/L,胰淀粉酶1529U/L,脂肪酶1410U/L,白细胞计数12.7×10^9/L,中性粒细胞0.74,淋巴细胞0.16。腹部超声检查和磁共振胰胆管造影示胰腺弥漫性增大、胰腺周围有液性渗出,诊断为急性胰腺炎。停用塞来昔布,禁食,给予营养支持和抑酶、抑酸、抗感染治疗13d,患者腹痛、腹胀消失,实验室检查示淀粉酶86U/L,胰淀粉酶48U/L,脂肪酶55U/L,白细胞计数7.2×10^9/L,中性粒细胞0.65,淋巴细胞0.32。胰腺CT示胰头、胰体和胰尾位于同一层面,形态及大小基本正常。 相似文献
2.
3.
《中国新药与临床杂志》2015,(6)
目的评价塞来昔布在痔疮手术中的超前镇痛效果。方法 40例择期行痔疮手术患者随机分为两组,每组20例。所有患者均采用连续硬膜外阻滞麻醉,试验组术前2 h予塞来昔布400 mg口服,对照组不服药物。采取疼痛视觉模拟量表评分(VAS)法评估患者术后1~3 d镇痛效果,并记录镇痛药应用情况。采用酶联免疫吸附法检测手术前后患者血清环加氧酶2(COX-2)和前列腺素E2(PGE-2)水平。结果术后第1日试验组创面疼痛VAS低于对照组(P<0.05),术后第2、3日两组VAS差异无显著意义(P>0.05)。术后3 d内试验组使用阿片类药物次数少于对照组(P<0.05)。术前两组血清COX-2、PGE-2水平均无显著差异(P>0.05),术后试验组血清COX-2水平下降(P<0.05),而对照组升高(P<0.05),组间差异显著(P<0.05),两组血清PGE-2水平均无明显变化(P>0.05)。结论塞来昔布超前镇痛能够减轻痔疮手术患者术后疼痛,降低患者COX-2水平。 相似文献
4.
5.
高效液相色谱法测定塞来昔布胶囊中塞来昔布的含量 总被引:1,自引:0,他引:1
目的 建立测定塞来昔布胶囊中塞来昔布含量的反相高效液相色谱法。 方法 以美国 Dikma公司 Diamonsil TMC1 8反相柱 ( 2 5 0 mm×4.6mm,5 μm)为色谱柱 ,流动相为甲醇 -超纯水 ( 85∶ 15 ,V/V) ,流速为 0 .8m L· min- 1 ,检测波长 2 5 4nm,柱温 40℃ ,进样量为 5 μL。考察了流动相不同配比对塞来昔布色谱行为的影响。 结果 塞来昔布与胶囊剂辅料及其杂质可完全分离 ;分析方法的定量测定下限为 2 5μg· m L- 1 ,线性范围 :2 5~ 10 0 0 μg·m L- 1 ,回归方程为 C=1.86× 10 - 2 F+1.84× 10 - 1 ,r=0 .999( n=8) ,平均回收率为 98.2 3 %,RSD=0 .47%。 结论 该方法灵敏、准确、简单、快速、可用于塞来昔布胶囊的含量测定 相似文献
6.
塞来昔布引起急性渗出性多形性红斑 总被引:1,自引:0,他引:1
1名56岁男性患者,因风湿性关节炎口服塞来昔布200mg。约2h后双上肢出现散在的多形性红斑,随即红斑遍布全身,伴灼热、瘙痒、渗出,患者表现为发热(T38℃)、胸痛、排尿困难,眼睑和上唇水肿,口腔黏膜和尿道口充血。实验室检查:WBC 10.5×10^9/L,N0,709,L0.201。给予抗过敏和对症治疗3d后,症状缓解,1周后红斑完全消退,但皮肤留下明显色素沉着。 相似文献
7.
目的探讨塞来昔布及帕瑞昔布在全髋关节置换术中的超前镇痛效果。方法将69例行全髋关节置换术的患者随机分为超前镇痛组36例和传统镇痛组33例。超前镇痛组围手术期应用塞来昔布及帕瑞昔布,传统镇痛组术前不给予任何镇痛药物,术后2组患者出现剧烈疼痛时,辅助其他类镇痛药物治疗。分别记录2组患者术后第2、4、8、12、24、48小时VAS评分、辅助其他镇痛药物的例数及不良反应。结果超前镇痛组术后各时点VAS评分小于传统镇痛组,且术后镇痛药物辅用率为5.6%,低于传统镇痛组的30.3%,差异均有统计学意义(P<0.05)。2组术后均无过敏反应、消化道出血以及心、脑血管等系统并发症发生。结论全髋关节置换围手术期应用塞来昔布及帕瑞昔布超前镇痛,无明显不良反应,临床镇痛效果良好。 相似文献
8.
目的为加强塞来昔布原料药的质量控制,合成了塞来昔布的有关物质。方法以甲基取代的苯乙酮为起始原料,经Claisen缩合,再分别与水合肼和对氨磺酰基苯肼盐酸盐缩合,制得目标化合物。结果与结论目标化合物的结构经1H-NMR、MS确证,合成的杂质可以作为塞来昔布原料药质量控制的有关物质对照品。该方法条件温和、原料易得、操作简单。 相似文献
9.
塞来昔布不比双氯芬酸好 总被引:1,自引:0,他引:1
黄世杰 《国外医学(药学分册)》2003,30(4):252-253
对于接受治疗的有消化道并发症危险的骨关节炎病人 ,一项新的研究结果提示 ,辉瑞 /法玛西亚公司的COX 2抑制剂塞来昔布 (celecoxib ,Celebrex)在降低复发性消化道出血方面 ,不比非甾体类抗炎老药双氯芬酸 (diclofenac)加用奥美拉唑 (omeprazole ,Losec)好。COX 2抑制剂主要优点是比价格便宜的非甾体类抗炎老药的消化道安全性高 ,但自塞来昔布CLASS研究结果发表以来 ,专家们对此颇有争论 ,对较新的COX 2药物心血管的安全性也有疑问。虽然美国销售的塞来昔布标签上已标明 ,该药与非甾体类抗炎老药比较未发现增加心血管病的危险。最近法… 相似文献
10.
目的 观察帕瑞昔布联合塞来昔布在妇科腹腔镜手术的镇痛效果和安全性, 为临床术后镇痛提供参考。方法 选择全麻下妇科腹腔镜手术患者158例, 随机分为观察组与对照组, 每组79例。观察组术前24小时给塞来昔布200 mg口服, 术前12小时塞来昔布200 mg口服, 切皮前30分钟给予帕瑞昔布40 mg静脉注射, 手术结束前30分钟给予帕瑞昔布40 mg静脉注射, 术后12小时帕瑞昔布40 mg静脉注射。对照组手术结束前30分钟给予帕瑞昔布40 mg静脉注射, 术后12小时生理盐水2 mL静脉注射。两组术后若VAS评分>4分, 则追加曲马多。记录两组患者术后清醒拔管1、4、8、12、24、48与72小时的VAS 评分与追加曲马多药物剂量, 统计分析术后不良反应发生情况、术前术后焦虑抑郁评分及术后慢性疼痛发生情况。结果 观察组各个时点的VAS评分均低于对照组, 差异有统计学意义(P<0.05);观察组患者术后并发症较对照组少, 差异有统计学意义(P<0.05); 观察组术前术后焦虑抑郁评分差值与对照组比较, 差异有统计学意义(P<0.05)。结论 帕瑞昔布联合塞来昔布在妇科腹腔镜手术术后镇痛有明显效果, 减少了术后镇痛药物并发症发生, 降低了术后疼痛评分, 减少了其他类镇痛药使用量, 缓解了术后焦虑抑郁情绪, 预防了患者术后慢性疼痛的发生。 相似文献
11.
目的探讨白三烯B4(LTB4)在儿童幽门螺杆菌(H.pylori)相关性胃炎发生中的作用。方法经胃镜确诊的胃炎45例患儿中,H.pylori阳性23例,H.pylori阴性22例。用ELISA法同时检测患儿血清及胃液中LTB4水平。结果 H.pylori阳性患儿血清LTB4为(2.063±1.016)ng/L,明显高于H.pylori阴性患儿的(0.441±0.894)ng/L(P<0.01);H.pylori阳性组胃液中LTB4浓度亦高于H.pylori阴性组(P<0.05)。结论 LTB4可能参与并促进H.pylori相关性胃炎发生、发展。 相似文献
12.
目的探讨砒石对哮喘小鼠的治疗作用及对肺组织LTB4、LTC4水平的影响。方法建立小鼠卵蛋白哮喘模型,灌胃给予砒石等药,对肺泡灌洗液进行白细胞分类计数,肺组织切片HE染色观察病理变化,用ELISA法检测肺组织匀浆LTB4、LTC4含量。结果哮喘组小鼠肺组织匀浆中LTB4、LTC4含量较生理盐水对照组升高。砒石1.25mg/kg能降低哮喘小鼠肺组织LTB4的含量;砒石0.625mg/kg可降低哮喘小鼠肺组织中LTC4水平至正常。砒石不能影响哮喘小鼠肺泡灌洗液中白细胞分类百分比。结论肺组织中LTB4、LTC4水平的增高可能在哮喘的发病中起作用。砒石能减轻哮喘小鼠肺的病理损害,降低哮喘小鼠肺组织LTB4、LTC4水平,从而表现出抗哮喘的活性。 相似文献
13.
Schiffmann S Maier TJ Wobst I Janssen A Corban-Wilhelm H Angioni C Geisslinger G Grösch S 《Biochemical pharmacology》2008,76(2):179-187
Celecoxib, a COX-2 (cyclooxygenase-2)-selective inhibitor (coxib), is the only NSAID (non-steroidal anti-inflammatory drug) that has been approved for adjuvant treatment of patients with familial adenomatous polyposis. To investigate if the anti-proliferative effect of celecoxib extends to other coxibs, we compared the anti-proliferative potency of all coxibs currently available (celecoxib, rofecoxib, etoricoxib, valdecoxib, lumiracoxib). Additionally, we used methylcelecoxib (DMC), a close structural analogue of celecoxib lacking COX-2-inhibitory activity. Due to the fact that COX-2 inhibition is the main characteristic of these substances (with exception of methylcelecoxib), we conducted all experiments in COX-2-overexpressing (HCA-7) and COX-2-negative (HCT-116) human colon cancer cells, in order to elucidate whether the observed effects after coxib treatment depend on COX-2 inhibition. Cell survival was assessed using the WST proliferation assay. Apoptosis and cell cycle arrest were determined using flow cytometric and Western blot analysis. The in vitro results were confirmed in vivo using the nude mouse model. Among all coxibs tested, only celecoxib and methylcelecoxib decreased cell survival by induction of cell cycle arrest and apoptosis and reduced the growth of tumor xenografts in nude mice. None of the other coxibs (rofecoxib, etoricoxib, valdecoxib, lumiracoxib) produced anti-proliferative effects, indicating the lack of a class effect and of a role for COX-2. Our data emphasize again the outstanding anti-proliferative activity of celecoxib and its close structural analogue methylcelecoxib in colon carcinoma models in vitro and in vivo. 相似文献
14.
《Pharmacological reports : PR》2014,66(6):1060-1064
BackgroundGenetic variability in DNA repair genes may contribute to differences in DNA repair capacity and susceptibility to colon polyps and cancer. In this study, we examined the role of MGMT polymorphisms in colon polyps formation.MethodsPCR–SSCP analysis was performed included 254 patients with colon polyps and 330 controls.ResultsThe homozygous F84F genotype was significantly more prevalent in study group than in controls. The polymorphic allele 84F was more frequent appeared in group of older patients and in group of smoking patients. On the other hand, there were no association between 84F and gender, size of polyps, cancer family history.ConclusionsWe concluded that high frequency of 84F allele in the group of patients may suggest the role of the MGMT variant in colon polyps etiology. 相似文献
15.
One major role of alveolar macrophages is the production of eicosanoids, which modulate immune and inflammatory processes
in the lung. In this study, the effects were investigated of cadmium ions on the secretion of leukotriene (LT)B4 and prostaglandin (PG)E2, predominant products of lipoxygenase and cyclooxygenase, respectively. Cd2+ had an inhibitory effect on the secretion of LTB4 and PGE2 in response to A23187 stimulation at concentrations >3× 10-5 M. This effect can be explained by the inhibition of arachidonic acid (20 : 4) liberation from membrane phospholipids by
Cd2+, because Cd2+ inhibits both [3H]arachidonic acid (20 : 4) liberation from [3H]20 : 4-prelabeled macrophages and the cytosolic phospholipase A2 activity. At concentrations <3×10-5 M, Cd2+ had no effect on PGE2 secretion but showed an augmentation of LTB4 secretion. In vitro study using macrophage lysate showed enhanced LTB4 synthesis from arachidonic acid by Cd2+, which could be responsible for the augmentation of LTB4 secretion in cells. These results indicate that Cd2+ may increase inflammation by increasing LTB4 production in lung.
Received: 13 February 1996/Accepted: 23 April 1996 相似文献
16.
目的:探讨孟鲁司特对毛细支气管炎患儿血清白三烯D4和尿白三烯E4水平的影响。方法:选择毛细支气管炎患儿72例,随机分为实验组和对照组各36例。两组患儿均予以止咳化痰、解痉平喘和抗病毒等常规治疗,实验组在此基础上加用盂鲁司特咀嚼片2.5mg,每天1次,连用7d,比较两组患儿治疗前后血清白三烯D4和尿白三烯E4水平的变化,并进行临床疗效及安全性分析。结果:治疗7d后,两组患儿血清白三烯D4和尿白三烯E4水平均较治疗前均明显下降(P〈0.05或P〈0.01),且实验组下降比对照组更明显,两组比较差异有统计学意义(P〈0.05);实验组患儿临床总有效率94.44%,明显高于对照组的75.00%(X^2=5.26,P〈0.05);对照组和实验组患儿治疗期间分别出现不良反应2例和4例(X^2=0.18,P〉0.05),症状较轻,未出现严重药物不良反应。结论:孟鲁司特治疗婴幼儿毛细支气管炎疗效确切,安全性较佳,作用机制与降低血清白三烯D4和尿白三烯E4水平,减少白三烯的释放密切相关。 相似文献
17.
The binding sites for [3H]leukotriene C4 were studied in membrane preparations of mouse brain and liver. Isotherm binding analysis revealed one binding site with a Kd of 10.39±1.97 nM (Scatchard) or 10.15±1.00 nM (non-linear). The maximal binding capacity (Bmax) was 49.20±3.80 (Scatchard) or48.50±2.63 (non-linear) pmol/mg prot. Specific binding represented more than 90% of the total binding. In displacement reactions on brain membranes, LTC4 was 100 times more active than LTD4, which displayed 10 times the activity of GSH. Glutamic acid, bilirubin and hematin were inactive. The activity of LCT4 was slightly less on liver membranes than on brain membranes. Liver sites had some affinity for GSH but not for LTD4 bilirubin or hematin. The results support the hypothesis that LTC4 and its receptor may have a neuromodulatory function. 相似文献
18.
19.
高迁移率族蛋白1(High mobility group protein, HMGB1)作为炎症反应的关键调节分子,能够通过其下游受体晚期糖基化终末产物受体(RAGE)、Toll样受体(TLR)等来发挥促炎等作用。大量研究表明前列腺炎症为前列腺早期疾病发展提供了免疫微环境,促进前列腺上皮细胞增生,作用于前列腺间质内的免疫细胞,促进免疫细胞分泌促炎因子白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)等。本文全面综述了高迁移率族蛋白1及其下游受体在前列腺相关疾病中的作用关系,为前列腺炎和前列腺癌相关免疫疾病的转化治疗提供一种参考。 相似文献
20.
摘 要 目的:建立塞来昔布中基因毒性杂质对磺酰胺基苯肼盐酸盐的含量测定方法。方法: 采用HPLC法,色谱柱:以100%多孔渗水石墨为填料的Hypercarb系列C18柱(150 mm×4.6 mm,3 μm);流动相:10 mmol·L-1乙酸铵水溶液-甲醇(50∶50)和甲醇,梯度洗脱;流速:0.8ml·min-1;检测波长:220 nm;柱温:35 ℃;进样量:20 μl。结果: 对磺酰胺基苯肼盐酸盐在99.897~599.382 ng·ml-1(r=0.998 2)浓度范围内与峰面积呈良好的线性关系。平均回收率为97.4%(RSD=3.0%,n=9)。结论: 该方法简便、准确,可用于塞来昔布中对磺酰胺基苯肼盐酸盐的含量测定。 相似文献